Scientists might have found a method to reverse the menopause, enabling girls experiencing it to ovulate and release fertile eggs.
The findings couldn’t only help girls who desire to have kids but also those who’ve experienced early menopause, where symptoms start before the age of 40.
Researchers said a blood treatment including platelet-rich plasma (PRP) could hold the solution for menopausal women who need kids.
“It offers a window of hope that menopausal women will have the ability to get pregnant using their own genetic material,” lead researcher Konstantinos Sfakianoudis, from Greek fertility practice Genesis Athens, told New Scientist.
PhotoAlto/Frederic Cirou via Getty Images
PRP is popular to accelerate the repair of damaged bones and muscles. Scientists consider it arouses tissue regeneration.
Sfakianoudis and his team found that old ovaries are also rejuvenated by PRP.
In menopausal women, an injection empowered them to gather and fertilise the eggs that were discharged and of PRP into the ovaries helped to restart their menstrual cycles.
Out of 30 girls older 46-49 injected with PRP, two thirds managed to have their eggs fertilised and isolated.
Among the study’s participants had been since the age of 40 for five years, in the menopause. Six months after having injected into her ovaries, she experienced a span.
Three eggs were taken by research workers from the girl, two of which have been fertilised by her husband’s sperm. It’s expected that these embryos will be implanted into her uterus so she can produce kids.
The team expects to trial this treatment in postmenopausal girls.
It’s believed the injection of PRP works by exciting a few stem cells accountable for making new eggs throughout a girl’s life. It’s not impossible that PRP supports these stem cells create hormones that get girls ovulate and to regenerate tissue.
Professor Geeta Nargund, medical director of Create Fertility practices, told The Huffington Post UK that additional studies must make sure the security of eggs using this technique.
She wrote: “ Until we confirm it is moral and safe, I ‘d encourage caution.
“We additionally have to contemplate the wellbeing of girls and kids before offering this technology to postmenopausal girls.”
Sfakianoudis’ team need to now run larger studies to understand how successful the treatment is.
The findings from their research were presented at the European Society of Human Reproduction and Embryology annual meeting in Helsinki, Finland, before this month.